Leveraging Insights from Antisense Oligonucleotide Drugs to Enhance Efficacy of Small Molecule Therapies

Time: 11:50 am
day: Day Two


• Consideration and exploration of oligonucleotide and anti-sense
molecule approaches
• Harnessing successes from large molecule strategies to implement in
small molecule design and progression
• Understanding important preclinical ASO data in large molecule
approaches to take back to the clinic
• How can the small molecule community compliment and build on proofof-
concept data?